159 related articles for article (PubMed ID: 16537407)
1. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
Varga JL; Schally AV; Csernus VJ; Zarándi M; Halmos G; Groot K; Rékási Z
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):692-7. PubMed ID: 9892695
[TBL] [Abstract][Full Text] [Related]
4. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
5. Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.
Varga JL; Schally AV; Horvath JE; Kovacs M; Halmos G; Groot K; Toller GL; Rekasi Z; Zarandi M
Proc Natl Acad Sci U S A; 2004 Feb; 101(6):1708-13. PubMed ID: 14755056
[TBL] [Abstract][Full Text] [Related]
6. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
Kovacs M; Zarándi M; Halmos G; Groot K; Schally AV
Endocrinology; 1996 Dec; 137(12):5364-9. PubMed ID: 8940358
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Rekasi Z; Varga JL; Schally AV; Halmos G; Groot K; Czompoly T
Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1218-23. PubMed ID: 10655511
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
[TBL] [Abstract][Full Text] [Related]
11. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
Zarandi M; Horvath JE; Halmos G; Pinski J; Nagy A; Groot K; Rekasi Z; Schally AV
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12298-302. PubMed ID: 7991622
[TBL] [Abstract][Full Text] [Related]
13. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
[TBL] [Abstract][Full Text] [Related]
14. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.
Kovacs M; Kineman RD; Schally AV; Zarandi M; Groot K; Frohman LA
Endocrinology; 1997 Nov; 138(11):4536-42. PubMed ID: 9348175
[TBL] [Abstract][Full Text] [Related]
15. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
Schally AV; Wang H; He J; Cai R; Sha W; Popovics P; Perez R; Vidaurre I; Zhang X
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12028-12033. PubMed ID: 30373845
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.
Horváth JE; Zarándi M; Groot K; Schally AV
Endocrinology; 1995 Sep; 136(9):3849-55. PubMed ID: 7649091
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
[TBL] [Abstract][Full Text] [Related]
20. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Kahán Z; Varga JL; Schally AV; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
Breast Cancer Res Treat; 2000 Mar; 60(1):71-9. PubMed ID: 10845811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
